Sentence examples for more adverse prognostic from inspiring English sources

Moreover, there seems to have been some selection of men with more adverse prognostic factors for PET/CT scanning (Table 1).

However, the studied men were probably a selected group with more adverse prognostic factors and a higher than average risk of metastases, so the clinical value of choline PET/CT for the entire group of men with high-risk prostate cancer might have been overestimated.

This is only partly explained by a more adverse prognostic patient profile, including a higher stroke severity, and not by a poorer quality of acute hospital care.

In all cohorts, the median patient age was ≥70 years and most patients (82%) had two or more adverse prognostic factors.

Although longer follow-up is needed, temporal patterns suggest that radiation may contribute disproportionately to the development of BC with more adverse prognostic features than would be expected in the general population.

The poor prognosis appeared only partly to be explained by a more adverse prognostic patient profile, including a higher stroke severity, and not by a poorer quality of acute hospital care.

A recent review indicates that younger age is associated with more widespread DCIS, more adverse pathological prognostic factors, higher local recurrence rate and rate of invasive recurrence, and worse prognosis [ 8].

Whether the cases of breast cancer arising in BRCA1-2 positive women are different from those occurring in the general population in terms of biologic characteristics, response to treatment and eventual outcome has not been fully elucidated, although most reports suggest that BRCA1-2 positive cases differ from sporadic cases without familiarity for more frequent adverse prognostic factors [ 2].

Results outlined in Table 7 highlight once more the independent adverse prognostic effect of a low CD8+/ buds index after adjusting for these additional factors.

Women with missing stage data may also have more co-morbidity or other adverse prognostic factors than women with known stage, contributing to lower survival within each stage.

It is an independent adverse prognostic factor and, more importantly, it is currently the best predictive factor for the activity of trastuzumab, an anti-HER2 monoclonal antibody (MoAb), which has revolutionized the treatment of this breast cancer subgroup.